FIELD: medicine. SUBSTANCE: method involves administering 5-aminosalicylic acid as one of preparation (Salophalc, Mezacol, Salozinal) at a dose of 0.5-1.0 g 2-4 times a day from the first to the tenth therapy course day. Peroral and rectal administration of 5- aminosalicylic acid and peroral administration of a dietetic complex additive at a dose of 0.9-1.8 g 2-3 times a day are combined from the eleventh to the thirtieth day. The dietetic additive only is administered at the last 10 days of the treatment course at the same therapeutic dose. EFFECT: eliminated energy deficiency and inflammation in the intestine; enhanced effectiveness of treatment course. 3 cl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING INFLAMMATORY DISEASES OF TERMINAL COLON | 2022 |
|
RU2807235C1 |
METHOD OF TREATING ULCERATIVE COLITIS | 2023 |
|
RU2807131C1 |
METHOD FOR RECTAL APPLICATION OF OZONE IN A MODEL OF ULCERATIVE COLITIS | 2022 |
|
RU2787973C1 |
METHOD OF TREATING ULCERATIVE COLITIS | 2023 |
|
RU2814765C1 |
METHOD FOR INTRAPERITONEAL APPLICATION OF MEDICAL OZONE FOR TREATING ULCERATIVE COLITIS | 2021 |
|
RU2782488C1 |
METHOD FOR INDIVIDUAL SENSITIVITY TO PREPARATIONS OF 5-AMINOSALYCILIC ACID (5-ASA) IN PATIENTS WITH ULCEROUS COLITIS | 2005 |
|
RU2287819C1 |
METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES | 2009 |
|
RU2394571C1 |
DOSAGE FORM FOR TREATING AND PREVENTING ULCERATIVE COLITIS, CONTAINING PEGYLATED LIPOSOMAL FORM OF ERYTHROPOIETIN IN FORM OF SUPPOSITORIES, HAVING ANTI-INFLAMMATORY AND IMMUNOMODULATORY EFFECT | 2020 |
|
RU2740060C1 |
METHOD FOR EVALUATING CLINICAL EFFECTIVENESS IN ULCERATIVE COLITIS | 2012 |
|
RU2504779C1 |
METHOD OF TREATING PATIENTS WITH ULCERATIVE COLITIS | 2009 |
|
RU2419443C1 |
Authors
Dates
2001-04-27—Published
2000-09-04—Filed